Newland Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Operating Revenue	662.81	720.99	643.85	621.21	508.93
Other Revenue	9.57	5.44	7.59	6.15	4.91
Revenue	672.38	726.44	651.44	627.36	513.84
Revenue Growth (YoY)	-7.44%	11.51%	3.84%	22.09%	18.63%
Cost of Revenue	447.24	437.43	392.84	404.01	307.82
Gross Profit	225.14	289	258.6	223.36	206.02
Selling, General & Admin	55.91	47.62	44.49	38.83	31.56
Research & Development	46.18	55.49	51.96	30	20.59
Other Operating Expenses	4.43	2.71	3.89	6.99	6.4
Operating Expenses	105.66	108.1	96.75	78.04	69.69
Operating Income	119.49	180.91	161.85	145.31	136.33
Interest Expense	-0.21	-0.09	-0.13	-6.88	-6.71
Interest & Investment Income	10.94	16.7	19.63	1.34	0.26
Currency Exchange Gain (Loss)	-0.03	0.25	0.06	0.29	-0.13
Other Non Operating Income (Expenses)	-0.02	-0.06	-0.12	-0.09	-0.06
EBT Excluding Unusual Items	130.16	197.7	181.29	139.97	129.69
Gain (Loss) on Sale of Investments	0.19	-0.23	0.04	1.36	0.17
Gain (Loss) on Sale of Assets	-	-	0.07	-0.44	-0.21
Asset Writedown	-1.49	-2.62	-1.46	-0.32	-0.11
Other Unusual Items	5.26	2.5	1.22	2.31	2.4
Pretax Income	134.12	197.35	181.16	142.88	131.94
Income Tax Expense	14.06	24.34	23.96	11.17	17.11
Earnings From Continuing Operations	120.07	173.01	157.2	131.71	114.82
Minority Interest in Earnings	1.18	0.62	1.78	0.6	0.15
Net Income	121.25	173.63	158.98	132.3	114.98
Net Income to Common	121.25	173.63	158.98	132.3	114.98
Net Income Growth	-30.17%	9.21%	20.16%	15.07%	-2.94%
Shares Outstanding (Basic)	391	395	391	302	294
Shares Outstanding (Diluted)	391	395	391	302	294
Shares Change (YoY)	-0.88%	1.05%	29.52%	2.59%	0.64%
EPS (Basic)	0.31	0.44	0.41	0.44	0.39
EPS (Diluted)	0.31	0.44	0.41	0.44	0.39
EPS Growth	-29.54%	8.08%	-7.22%	12.17%	-3.36%
Free Cash Flow	15.55	15.97	162.94	8.5	23.68
Free Cash Flow Per Share	0.04	0.04	0.42	0.03	0.08
Dividend Per Share	0.200	0.400	0.204	0.170	-
Dividend Growth	-50.00%	95.98%	19.99%	-	-
Gross Margin	33.48%	39.78%	39.70%	35.60%	40.09%
Operating Margin	17.77%	24.90%	24.85%	23.16%	26.53%
Profit Margin	18.03%	23.90%	24.40%	21.09%	22.38%
Free Cash Flow Margin	2.31%	2.20%	25.01%	1.35%	4.61%
EBITDA	172.06	216.31	190.69	167.38	157.19
EBITDA Margin	25.59%	29.78%	29.27%	26.68%	30.59%
D&A For EBITDA	52.57	35.4	28.84	22.06	20.86
EBIT	119.49	180.91	161.85	145.31	136.33
EBIT Margin	17.77%	24.90%	24.85%	23.16%	26.53%
Effective Tax Rate	10.48%	12.33%	13.23%	7.82%	12.97%
Revenue as Reported	672.38	726.44	651.44	627.36	513.84
Advertising Expenses	1.1	0.85	0.51	0.2	0.28

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.